01—Abstract
Summary
Summary of the 8-K filed July 3, 2024. Cited figures are marked; the original filing is the authoritative source.
AbbVie Inc. (ABBV) has filed a Current Report on Form 8-K to provide an update on expected financial results for the second quarter of 2024.
The company anticipates reporting acquired intellectual property rights and development (IPR&D) and milestones expenses of $937 milliona pre-tax. This expense is projected to have an unfavorable impact of $0.52 per share on both GAAP and adjusted non-GAAP diluted earnings per share for the quarter. While these figures are preliminary and subject to finalization, AbbVie has updated its full-year 2024 adjusted diluted earnings per share guidance.
The revised range, now including the impact of the second quarter IPR&D and milestones expense, is between $10.61b and $10.81. The company also provided an updated second quarter 2024 adjusted diluted earnings per share guidance range of $2.53 to $2.57, reflecting this expense. Investors should note that acquired IPR&D and milestones expenses are inherently unpredictable in timing and occurrence, and AbbVie does not typically forecast them beyond the first quarter.
02—Key points
Key Highlights
- AbbVie expects $937 million in acquired IPR&D and milestones expenses in Q2 2024.
- This expense will negatively impact Q2 2024 GAAP and adjusted diluted EPS by an estimated $0.52.
- Full-year 2024 adjusted diluted EPS guidance is now $10.61 - $10.81, reflecting the Q2 expense.
- Q2 2024 adjusted diluted EPS guidance is revised to $2.53 - $2.57.
- The company does not forecast acquired IPR&D and milestones expenses due to their uncertain nature.
- The provided guidance is preliminary and subject to final financial closing procedures.
03—Questions
Frequently Asked Questions
What is the primary reason for the financial update in this 8-K filing?
The primary reason for this 8-K filing is to inform investors about a significant acquired intellectual property rights and development (IPR&D) and milestones expense expected in the second quarter of 2024 and its impact on the company's earnings per share.
How does the $937 million expense affect AbbVie's earnings?
The $937 million pre-tax expense is projected to reduce both GAAP and adjusted non-GAAP diluted earnings per share by approximately $0.52 for the second quarter of 2024. This expense is a key factor in the updated guidance.
Have AbbVie's full-year 2024 earnings expectations changed?
Yes, AbbVie has updated its full-year 2024 adjusted diluted earnings per share guidance. The new range is $10.61 to $10.81, which now incorporates the estimated impact of the second quarter IPR&D and milestones expense.
Why doesn't AbbVie typically forecast acquired IPR&D and milestones expenses?
AbbVie does not forecast these expenses because their occurrence and timing are uncertain. They are typically incurred upon the execution of collaborations, licensing agreements, or other asset acquisitions, making them difficult to predict.
04—Continue